Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.255 USD | +0.46% | +12.46% | +83.62% |
May. 14 | Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours | MT |
May. 14 | Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+83.62% | 606M | |
+53.05% | 63.85B | |
-2.49% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.22% | 26.52B | |
-21.39% | 18.69B | |
+2.70% | 12.73B | |
+22.45% | 12.11B | |
+27.45% | 12.07B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $7 From $6, Keeps Overweight Rating